Alpha Tau Medical Business Summary

Alpha Tau Medical Ltd. (DRTS) is a clinical-stage oncology therapeutics company that generates revenue through the development and future commercialization of its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. The company’s business model centers on the production and sale of Radium-224 impregnated sources, which are delivered intratumorally to treat solid tumors via high-energy alpha radiation. Primary business segments are categorized by clinical application across diverse oncology indications, including recurrent cutaneous squamous cell carcinoma (cSCC), pancreatic cancer, glioblastoma multiforme (GBM), and prostate cancer. Alpha Tau competes directly with radiopharmaceutical and brachytherapy leaders such as Novartis (Pluvicto), Bayer (Xofigo), Perspective Therapeutics, and Sirtex Medical. Unlike systemic targeted alpha therapies or traditional beta-emitting brachytherapy, Alpha Tau occupies a unique market niche by providing highly localized, potent alpha-irradiation that spares surrounding healthy tissue while potentially triggering a systemic anti-tumor immune response. The company was founded in 2016 by a multidisciplinary team from Tel Aviv University, including Chief Physics Officer Prof. Itzhak Kelson and Chief Scientific Officer Prof. Yona Keisari, who co-invented the Alpha DaRT technology. The leadership team is headed by CEO and Chairman Uzi Sofer, a seasoned medical device executive who previously co-founded and led Brainsway (BRNS) through its IPO and multiple FDA approvals. Other key executives include CFO Raphi Levy, CTO Ronen Segal, and Chief Medical Officer Dr. Robert Den. Alpha Tau’s strategic positioning is bolstered by a notable partnership with Oramed Pharmaceuticals, which serves as a strategic investor and is represented on the board by Nadav Kidron. The board also features industry veterans such as Dr. Morry Blumenfeld, a former Managing Director at GE Healthcare Israel, and Alan Adler, former CEO of Oridion Medical.